Skip to Content

News: Journal Watch

Journal Watch

Monday, March 1st, 2021

New strategy for reducing tumor growth Ann Richmond, PhD, and colleagues have discovered that blocking a certain signaling pathway boosts antitumor immunity and reduces tumor growth and metastasis in models of breast cancer and melanoma. The findings, reported Dec. 18, 2020, in the journal Cancer Immunology Research, add mechanistic insight and support for the therapeutic […]

Journal Watch

Wednesday, September 23rd, 2020

Study finds AI can categorize cancer risk of lung nodules Computed tomography scans for people at risk for lung cancer lead to earlier diagnoses and improve survival rates, but they can also lead to overtreatment when suspicious nodules turn out to be benign. A study for which Pierre Massion, MD, was the lead author published […]

Journal Watch

Wednesday, January 15th, 2020

New prostate cancer treatment concept Prostate cancer, the second leading cause of cancer-related death for men in the United States, is poorly responsive to immunotherapy. Recent clinical trials have hinted that combining immunotherapy and radiation therapy may be a powerful treatment approach for castration-resistant prostate cancer. Austin Kirschner, MD, PhD, and colleagues combined radiotherapy with […]

Journal Watch

Friday, August 2nd, 2019

Cancer prevention drug also disables H. pylori bacterium A medicine currently being tested as a chemoprevention agent for multiple types of cancer has more than one trick in its bag when it comes to preventing stomach cancer. Keith Wilson, MD, and J. Carolina Sierra, PhD, reported in the March 12 issue of Proceedings of the […]

Journal Watch

Thursday, January 3rd, 2019

Glutamine metabolism affects T cell signaling & function The cellular nutrient glutamine launches a metabolic signaling pathway that promotes the function of some immune system T cells and suppresses others, Vanderbilt researchers have discovered. They show that a drug that inhibits glutamine metabolism — currently in clinical trials as an anticancer agent — might also […]

Journal Watch

Tuesday, May 22nd, 2018

Novel anti-cancer drug resistance mechanism identified Vanderbilt investigators have discovered a novel nongenetic cause of resistance to cetuximab, a mainstay of treatment for advanced colorectal cancer. The findings of Robert Coffey Jr., MD, and colleagues, published Oct. 16, 2017, in Nature Medicine, suggest a strategy for overcoming this resistance, which their research indicates is due […]

Journal Watch

Wednesday, November 22nd, 2017

New target for colorectal cancer  In a study published March 6 in the journal Oncogene, Dana Hardbower, Ph.D., Keith Wilson, M.D., and colleagues demonstrated that epidermal growth factor receptor (EGFR) signaling in macrophages is associated with increased colitis-associated colon cancer development. While inflammatory bowel disease and colitis can increase the risk of colon cancer, the […]

Journal Watch

Wednesday, May 31st, 2017

Discovery offers new insight on lung cancer risk Researchers have discovered a proteomic “signature” from the airways of heavy smokers that could lead to better risk assessment and perhaps new ways to stop lung cancer before it starts. The findings, reported Nov. 17, 2016, in JCI Insight, are based on the observation that otherwise normal-looking […]

Journal Watch

Tuesday, December 6th, 2016

VUMC study: current cancer drug discovery method flawed The primary method used to test compounds for anti-cancer activity in cells is flawed, Vito Quaranta, M.D., and colleagues reported May 2 in Nature Methods. The scientists developed a new metric to evaluate a compound’s effect on cell proliferation. The old system counted how many cancer cells […]

Recent Publications by VICC Researchers

Thursday, June 2nd, 2016

Study identifies new culprit in lung cancer development A microRNA—a small piece of RNA involved in regulating gene expression—functions as an oncogene to drive the development of lung cancer, Vanderbilt-Ingram Cancer Center investigators have discovered. The microRNA, known as miR-31, is expressed at high levels in human lung adenocarcinoma, and its expression correlates with reduced […]

Next Page »